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Abstract
Objectives: We aimed to improve the decision quality and outcomes for families with children or adolescents with diabetes
considering continuous sub-cutaneous insulin infusion (CSII).
Methods: A mixed method study involved three focus groups with youth, parents and clinicians to provide experience
information as background to the development of a decision aid (DA). A pre-test (T1) and post-test (T2) evaluation of the
DA with a convenience sample of five families considering initiating CSII.
Results: The focus group data showed that families found the move to CSII to be generally empowering with adolescents
engaging with the technology quickly, and that experiential information from others was important in the process.
Participants increased their knowledge and decreased decisional conflict after using the DA from T1 to T2. Preferred
option measurement indicated that at T1, three participants were ‘unsure’ and two participants’ preferred option was
CSII. After exposure to the DA at T2, those who were previously unsure had a preferred option of CSII with a resulting five
people with a preferred option of CSII.
Conclusions: The results from this study suggest that transitioning to CSII for paediatric and adolescent patients and their
carers may be assisted by a DA and that participants felt empowered to a make decision regarding CSII when using the
PANDANI DA. The quasi-experimental design without randomisation or control group was a study limitation caused by the
small number of participants. Expanding this pilot research into a randomised control trial would decrease the threat to
validity from other possible explanations for the improvement in decisional conflict, such as nurse educators.
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Introduction
The incidence of diabetes is increasing in Australia and
around the world1 with 5.1% of Australian children
aged 14 years and under diagnosed with type 1 diabetes
(T1D) and two-fifths of these placed on insulin pump
therapy.2 Little is known though about how families of
children with T1D cope with the transition to more
intensive and high-tech management, and whether deci-
sion support influences their choices around continu-
ous sub-cutaneous insulin infusion (CSII). We report
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the outcomes of the Paediatric and Adolescent iNsulin
pump Decision Aid Project (PANDANI) that aimed to
understand the transition experience to CSII and to
improve the decision quality and outcomes for families
through the development and piloting of a decision
aid (DA).
Decision support involves providing information to
improve knowledge and awareness of resources to
enable realistic expectations. DAs assist clarification
of values and help people develop a sense of efficacy
when making choices.3 Decisional regret is associated
with poorer quality of life after treatment for serious
illnesses such as cancer, with under-informed patients
being at greater risk of regret.3 Using DAs, people may
feel more confident in making a timely choice, experi-
ence less decisional conflict, less delay in making deci-
sions, less decisional regret, and fewer discontinued
decisions.4,5 DAs are particularly useful in complex sit-
uations where outcomes may involve trade-offs
between risks and benefits, or when choices are depen-
dent more on values and beliefs than outcomes. Unlike
educational materials, they focus on options in a spe-
cific and personalised manner that facilitates decision
making and empowers people to synthesise informa-
tion and preferences so that they can make informed
and person-centred health care decisions.
Intensive diabetes management leads to improved
glycaemic control and a reduction in diabetes-related
complications.6 To achieve this with traditional treat-
ment options requires multiple injections of insulin
every day plus multiple finger-prick testing for blood
glucose levels (BGLs).7 CSII instead involves wearing a
small electronic device that delivers insulin subcutane-
ously via a cannula with pre-programmed doses. The
cannula requires changing every 2–3 days, thereby
decreasing the ‘injections’.
CSII provides greater lifestyle flexibility in food
choices and activity with less risk of BGL outside
the optimal range. However, there is less evidence of
the benefits of CSII in paediatric populations when
compared to adult populations, though research indi-
cates that CSII improves outcomes and quality of
life.1,8 Study results are somewhat mixed but have dem-
onstrated the efficacy of CSII in decreasing hypogly-
caemia9 and achieving near-normoglycaemia in
children10–12 compared with traditional injections.
This is important because normoglycaemia helps to
prevent acute and chronic metabolic complications,
life-threatening diabetic ketoacidosis or severe hypo-
glycaemia leading to coma, seizure and/or death.13
Apart from the insulin delivery function, CSII allows
data storage for BGLs, insulin doses, exercise and diet,
and interacts with software that provides data analysis.
CSII technology is rapidly improving and new devices
may have increased safety measures to prevent
hypoglycaemia.
Despite the many benefits of CSII, there are a
number of variables that affect successful uptake and
discontinuation rates. An evaluation in Ontario found
large variation in uptake of funded CSII in children,
greater discontinuation rates and a higher risk profile
for lower socioeconomic groups.14,15 Importantly,
there is a greater risk of discontinuation of pump use
during the first year of use,16 with puberty, or being
female, implicating peer pressure and negative body
image issues.11 Adolescents and families have also
reported periodic discontinuation of CSII during holi-
day periods and other ‘break periods’.8,16 For some,
discontinuation of CSII among these groups has been
attributed to a poor client match, as some clients may
not have the capacity to manage the procedures of
CSII.17 In some instances, CSII is also associated
with more rapid rates of ketoacidosis when compared
with injection therapy, a greater need for trained per-
sonnel and high upfront costs of pumps.9,18
For children considering CSII, the choice between
injection therapy and CSII needs to account for the
family and school context as well as the child and cli-
nician perspectives in order to account for the known
success factors.15 In the case of children using CSII,
needing to reverse an uptake decision quickly may
leave the child and/or family with a negative view of
CSII treatment and an unwillingness to return to it at a
more appropriate life stage, particularly where the cost
of pumps are a major consideration.17
Over 500 aids have been developed globally and
DAs are now being viewed as a useful means to help
those with chronic conditions to make complex and
family-based decisions.3 Due to the complexity of mul-
tiple players in a child’s life, and the complexity of
factors affecting uptake and discontinuation, creating
a targeted DA for child and adolescent populations
when considering CSII appears a natural step. This
paper describes the experience of youth, parents and
clinicians in the transition to intensive technological
CSII, and the development feedback and piloting of a
DA for children and families considering CSII.
Methods
A mixed method study developed and evaluated the
DA with participatory input from paediatric and ado-
lescent patients and their families between 2014 and
2016. A review of literature identified the known cor-
relates of CSII success and failure, in order to encap-
sulate these into the DA. Focus groups were used to
assess decision-support needs through understanding
the experiences of young adults and parents who had
previously adopted CSII and feedback about the draft
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DA. The study then used a one-group pre-test–post-
test to evaluate the DA, which involved five families
from two sites within Tasmania, a state of Australia.
Three focus groups were held with one each for
clinicians, parents and young adult CSII users. Focus
groups are a useful way to understand diabetes-related
phenomena and develop interventions such as DAs.19
Participants for the focus group were recruited through
advertisements with the clinician professional bodies,
the key diabetes centres, and word of mouth, with
those interested contacting the researchers. People
under the age of 18 were excluded from the interview
stage. A semi-standardised set of questions (Table 1)
asked about the experience of transitioning to pump,
issues affecting decisions to use CSII, and feedback on
the draft DA.
Focus group 1 comprised two diabetes educators
and one paediatric registrar. Together, the three
female participants managed approximately 200 paedi-
atric and adolescent patients through diabetes clinics.
The participants related their comments exclusively to
the under-18-years age group. The second focus group
comprised six parents, all female. The age of their chil-
dren with T1D ranged from 2–15 years and they had
been diagnosed at least 1 year previously. The children
had various trajectories to CSII. Four of the children
had been on CSII for at least 3 years. One adolescent
had previously tried CSII, discontinued, then recon-
nected to CSII within the previous 6 months. A
second adolescent had begun CSII 3 weeks previously.
One preschool aged child had been placed on CSII
soon after diagnosis. The third focus group contained
two youths aged between 18 and 20 years who had
moved to CSII at the age of 14–15 years. Limitations
in ethics approval precluded our ability to interview
children and adolescents under the age of 18 years.
Feedback from the focus groups was used to develop
the PANDANI DA.20
A pre-test (T1) and post-test (T2) evaluation of the
DA was conducted with a convenience sample of five
Table 1. Focus group questions.
1 Introductions, participants may choose to use a pseudonym.
2 Participants are asked the following information:
a. Age and age of child if relevant
b. Relationship to child with type 1 diabetes – parent/guardian/clinician/teacher
c. Sex – M/F
d. Date of diagnosis if relevant.
3 Briefly tell me what each of you understand by type 1 diabetes.
4 Going around the group again, how did you first became aware of type 1 diabetes and what were your first personal
interactions with a child/adolescent with type 1 diabetes.
5 What is your experience of insulin pump therapy, and what involvement did you have (e.g. parent helping or using
pump, teacher, child using pump)?
6 In your experience, how do treatment processes affect the lives of children and families? (Prompt: regarding insulin
pump or regular injections, blood testing.) Prompt: What are the positives and the negatives?
7 In your opinion, which factors make insulin pump therapy successful?
8 In your opinion, which factors make insulin pump therapy difficult?
9 In your experience, what information and support would help children/families to cope with insulin pump therapy?
Prompt: How well do you feel that the current information meets these needs?
10 Considering the decision aid:
a. Is there additional information which needs to be added to adequately reflect your experiences in moving to
pump therapy?
b. Is there information which you consider would be better off removed from the decision aid?
c. Are there changes that you would make to the format or set out of the decision aid to increase readability and
helpfulness?
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families where the children/adolescents and parents
were considering initiating CSII, recruited between
August 2016 and November 2016. The project was
advertised through the state’s three diabetes centres
with 16 initial enquiries resulting in eight families con-
senting. Only five families completed the trial, one with
a child under 5 years of age, two with primary school
aged children and two with adolescents. Inclusion cri-
teria for patients were: the child/adolescent had T1D,
the child/adolescent was not already on an insulin
pump, the family or child/adolescent was open to the
idea of an insulin pump, the child/adolescent was under
the age of 18 years and the child/adolescent and fam-
ily’s written and spoken English language skills were
sufficient to exclude the need for an interpreter.
After obtaining informed consent, a researcher
administered the T1 questionnaire via phone link.
The T2 questions were administered approximately 6
weeks later. This interval period gave families time to
meet with their diabetes educator and also to use the
DA in a variety of situations. Five families completed
both T1 and T2. Standard demographic information
was collected. Ten diabetes knowledge questions
using five child-appropriate general diabetes knowledge
questions from the Michigan Knowledge Scale21 and
five insulin pump knowledge questions tested from
the Agency for Healthcare Research and Quality
(AHRQ) 22 were collected using true/false/don’t know
responses. The Decision Conflict Scale (DCS)23 and
questions about preferred choice (fixed dose injections,
multiple daily injections, insulin pump therapy, and not
sure) measured decision making. In the T2 intervention
an additional set of three questions were asked that
related specifically to the use of the DA intervention.24
Analysis
Focus group data were transcribed and thematically
analysed using inductive analysis and categorisation.
Descriptive characteristics for children and parents
are reported in Table 2 and changes in knowledge
were treated as T1 and T2. The DCS scores were con-
verted to a 0–100 scale. Paired t-tests (two-sided and
CI> .095) were used to compare mean changes in
scaled measurements of decisional conflict from T1 to
T2. Knowledge answers were converted to dichoto-
mous correct/incorrect answers.
Focus group findings
The focus group data showed that families found the
move to CSII to be generally empowering, with adoles-
cents engaging with the technology quickly. Both clini-
cians and parents of children with diabetes felt a DA
would be useful, and provided feedback on the final
draft of the DA.
Decision motivation: less needles and flexibility
The young adults reported that as adolescents they had
felt empowered by the flexibility that the pump offered,
Table 2. Demographic information for trial participants.
Count
Parent gender
Male 0
Female 5
Child gender
Male 4
Female 1
Child age in years
Less than 5 1
5–12 2
13–15 2
Australian born
Child 5
Highest education level: parent
Grade 10 1
Trade Certificate 2
University Bachelor 2
Financial stress measure
(can you get $2000 within 7 days?)
Yes 3
No 2
Clinic relationship
Mother 3
Father 0
Both parents 2
Note: This research was supported through a competitive grant.
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though this was not their primary consideration for
moving to a self-tracking device.
I came in for my usual check up and went home with a
pump on order . . . I suppose that it was a little unusual
but my overriding thought was less needles. I was sick
of the needles . . . It wasn’t really until after I got the
pump that I realised how good it was. I was a teenager
and for the first time I could sleep in (Youth,
Participant 1).
Our young adult participants reported that as adoles-
cents the flexibility CSII provided included simple
pleasures such as staying up late and being able to
sleep longer in the morning.
Transition to new technology CSII
The two youth reported being proud of their pump. It
was something new that everyone wanted to
engage with.
It was like a toy. I enjoyed getting to know how it
worked and what the best way to do things was
(Youth, Participant1).
I remember being proud and self-conscious at the same
time. It was a bit like show and tell. My family all
wanted to have a play with it (Youth, Participant 2).
As adolescents, they adapted easily to the new technol-
ogy and felt they really understood the implications of
their pump readings.
I was flying within a few days. It took a week at most to
work out what to do with it (Youth, Participant 2).
All focus group participants spoke about the need
for adequate support and education prior to adopt-
ing CSII.
So we push questions at young people and we say . . .
imagine you’ve got a pump on and I want you to write
up all the questions that come up – you’re having a
shower, you’re having a meal, playing footie, . . . what
comes up? (Clinician, Participant 1).
Clinicians concentrated on the child and the provision
of factual information for child and parent. Examples
included teaching carbohydrate counting and what to
do if the set falls out.
We take them through all the basics . . .. Set changes . . .
Then there is the technical stuff as . . . how to problem
solve (Clinician, Participant 2).
Avenues of support and information
Parents and clinicians identified a need for more expe-
riential information in preparing them for the intense
pressure at the initial change over to CSII. In addition
to the information provided by diabetes educators
and their paediatricians, parents wanted to discuss
the decision with people who had lived through
the experience.
I think we had lots of information and everyone kept
telling us, . . . ‘It’s like relearning diabetes all over
again’. . . . But that’s probably not very useful just
saying that without anything else. You know even
saying things like ‘have you thought about the practi-
calities’. I’m back to the meal preparation again. You
know, freezing some food, because I wish I had done
that (Carer, Participant 3).
Parents acknowledged that they received a significant
amount of information about CSII and the pump.
They received training about CSII, but were unpre-
pared for the mental and physical strain from transi-
tioning their child to CSII. They were unprepared for
the rigours of sleepless nights, the increased number of
finger pricks and CSII monitoring on a 24-hour basis
along with the need to absorb new information, count
carbs and address issues raised by third parties such
as schools.
I never saw it coming. I didn’t think I would ever feel
this low . . . I’m crap and my husband’s crap at the
moment and we’re just three weeks in. [Child’s]’s
back at school and he’s looking like crap. Pump’s
going really well though (Carer, Participant 2).
Clinicians reported that there was a greater ability to
problem solve with children/adolescents using CSII
and their parents because they could look through
the data sent to them without the need for scheduled
patient appointments. Combined with telephone calls,
the overall participation between clinicians and
patients increased and appointment time decreased.
Though there are other formal organisations that sup-
port people with diabetes and their families such as
Diabetes Australia, these were not mentioned as a
source of information, support or help in moving to
CSII. Overall, parents felt a need to hear first-hand
stories of the CSII journey from other parents who
understood the challenges of life with CSII.
Ensuring collaborative decision-making. Clinicians wanted
children to identify their treatment preference early in
the decision process to ensure the child wanted a
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treatment change. In some cases, parents initiated CSII
even though the child did not want it.
There was some question as to whether she really
wanted a pump. She is six years of age but from the
family point of view the pump was the best choice. This
young person we believe has been sabotaging her pump
and has now come out and said ‘I really don’t want the
pump’ (Clinician, Participant 1).
This story highlights the potential to disempower
children in planning treatment and the importance of
clinicians engaging with the child’s wants as well as
the carers’.
Engagement with third parties such as schools,
day-care, sporting clubs or other extra-curricular activ-
ity groups also occupied much of the carers’ time.
Moving to CSII intensified their involvement with
these groups as the change in treatment regime needed
to be explained to them. Carers reported varying degrees
of acceptance and support from these groups.
Following the focus groups, changes were made to
the DA. These changes included formatting changes,
the inclusion of additional information and additional
questions into the decision-making process. All focus
group participants suggested an electronic version of
the DA would be useful. The adolescent focus group
advised that they would not use a paper-based DA,
whereas the carer and clinician focus groups indicated
the value in having both a paper-based and electronic
version, particularly where they needed to engage with
third parties such as schools and day-care.
Decision aid evaluation results
Participants increased their knowledge and decreased
decisional conflict from T1 to T2. Preferred option
measurement indicated that at T1, three participants
were ‘unsure’ and two participants’ preferred option
was CSII. After exposure to the DA at T2, those who
were previously unsure had a preferred option of CSII
with a resulting five people with a preferred option
of CSII.
As shown in Table 3, the mean score for the DCS
significantly decreased after exposure to the DA, with
participants moving into the score range associated with
implementing decisions (<25). All subscales, apart
from Support, decreased post intervention (p< 0.05).
The subscale Uncertainty reflects items ranging from
‘feels extremely certain about best choice’ (score 0) to
‘feels extremely uncertain about best choice’ (score 100).
The Uncertainty results showed the largest decrease in
mean scores (p < 0.05). All participants demonstrated a
decrease in DCS, even those who did not change their
preferred option.
The general diabetes knowledge questions were
answered correctly pre intervention (with the exception
of one question: 2% incorrect) but 22% of the CSII-
related questions were incorrect. Table 4 shows the T1
and T2 answers to the five insulin pump knowledge
questions with only 6% of answers incorrect. The
response ‘I don’t know’ was treated as incorrect.
Discussion
This research highlights the potential of CSII as
empowering technology. Empowerment is the social
process of recognizing, promoting, and enhancing peo-
ple’s abilities to meet their own needs and problem
solve those issues through the mobilisation of resour-
ces.25 The acquisition and development of these resour-
ces and the ability to use them to problem solve and
enhance self-determination brings about a state of well-
ness. While the transition to CSII was more intensive,
Table 3. Decisional conflict scores and subscores.
Scalea
Pre-test,
mean SD
Post-test,
mean SD
P (paired
t-test)
Decision Conflict Scale 33.13 16.96 15.62 10.88 0.02
Uncertainty 51.67 33.02 18.33 16.03 0.05
Support 26.67 18.07 15.00 18.07 0.14
Effectiveness of decision 26.25 15.56 13.20 9.99 0.01
Value clarity 26.67 10.86 13.33 12.64 0.02
Informed 36.67 17.27 15.00 9.13 0.03
Note: aScores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict). Scores >37.5 are associated
with decision delay or feeling unsure and scores <25 are associated with implementing decisions.
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it was seen as empowering because it gave children,
families and clinicians timely information and allowed
a more flexible, normal, lifestyle. Clinicians provided
extensive support and information, but parents also
wanted peers’ experiential information to help them
prepare and cope with the physical and emotional
demands of moving to CSII.
The T1 and T2 DA intervention results suggest that
the DA provided decision support for those parents
and children who were making a decision about CSII.
While the small purposive sample size and the lack of a
control group limit the conclusions that can be drawn
from this study, the change in scores from the well-
validated DCS, do indicate that the participants
moved from a state of decisional conflict, with scores
associated with decision delay, to a state associated
with implementing decisions. The decrease in scores
also suggests that participants may be less likely to
change their minds, express decisional regret, and
blame their doctor or clinician for bad outcomes.26
Given the complexity of the change to CSII, the use
of a structured decisional aid is recommended.
Expanding this pilot research into a full RCT would
be useful to further examine the effect of the
PANDANI DA in this growing patient population.
The pilot study has also demonstrated that recruitment
of participants into this type of study would require
additional strategies, and that an electronic version of
the DA would be the preferred medium. Electronic
DAs have been found to be beneficial in other
circumstances.27
The findings from this research provide insight into
the transition experience of the participants. However,
recruitment difficulties meant that the small number of
participants in two of the focus groups limited the anal-
ysis. Recruitment difficulties also meant that two of the
focus groups contained only women. While families
engaged in the research had some diversity in terms
of economic status and educational attainment, it is
clear that they all provided a supportive environment
for diabetes management. It is possible that less sup-
portive environments may need additional strategies.
Strengths and limitations
This DA has been developed and strengthened through
a mixed method approach, which provided qualitative
perspectives. Results suggest further research is needed
that measures empowerment outcomes for children and
adolescents.
The quasi-experimental design without randomisa-
tion or control group was a study limitation resulting
from the small number of participants. Expanding this
pilot research into an RCT would decrease the threat to
validity from other possible explanations for the
improvement in decisional conflict, such as nurse edu-
cators. The pilot study has also demonstrated that
recruitment of participants into this type of study
would require additional strategies. Development of
an electronic version of the DA was suggested by the
Advisory Group and focus group participants.
Table 4: Diabetes Knowledge test results T1 and T2.
Correct T1 Incorrect T1 Correct T2 Incorrect T2
Question Code Count Count Count Count
Insulin pump therapy will
make me gain weight
K3.6T1 4 1 4 1
I can detach from my pump
for up to two hours provid-
ed I remember to bolus
K3.7T1 1 4 4 1
Insulin pumps are bulky and
uncomfortable to wear
K3.8T1 3 2 4 1
My eating times will be rigid if
I use insulin pump therapy
K3.9T1 4 1 5 0
I will not need to monitor
blood glucose levels if I get
an insulin pump
K3.10T1 4 1 5 0
Total 39 11 44 6
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Conclusion
CSII is a management device that may be used to
manage and reduce diabetes-related complications.
In this research, paediatric and adolescent patients
and their carers reported adapting well to CSII and
received benefits over and above the medical health
benefits sought from better management of BGLs.
The results from this study demonstrate that a DA
may assist the decision to adopt CSII for paediatric and
adolescent patients and families. Children, families and
clinicians reported feeling empowered by the dual-level
data collection of CSII leading to increased interactions
around diabetes management. For this to occur, clini-
cians need to ensure that children are involved in the
decision to change to CSII, whilst taking into account
overall family needs.
The research also found that the clinician focus is on
the patient rather than carer during the transition pro-
cess. Though parents were engaged with the process of
moving to CSII, parents did not feel that they were
adequately supported with practical help and tips
needed to ensure optimum carer self-care during the
transition period. Our DA filled this gap, but diabetes
educators could also work to improve peer-support
information for families.
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